Breast Cancer Timeliness to Care Based on Genetic Counseling Services

Background
To maximize genetic testing benefits, appropriate and timely risk management must be initiated. Germline mutations can identify patients for whom bilateral mastectomy is likely beneficial. In the United States, available data are limited regarding genetic testing of breast cancer patients at high risk regarding timing of testing relative to surgical treatment, surgical decision making, and treatment outcomes.

Objective
Analyze the impact of genetic testing results on timeliness to breast cancer care.

Methods
Objective
Analyze the impact of genetic testing results on timeliness to breast cancer care.

Background
To maximize genetic testing benefits, appropriate and timely risk management must be initiated. Germline mutations can identify patients for whom bilateral mastectomy is likely beneficial. In the United States, available data are limited regarding genetic testing of breast cancer patients at high risk regarding timing of testing relative to surgical treatment, surgical decision making, and treatment outcomes.

Objective
Analyze the impact of genetic testing results on timeliness to breast cancer care.

Exclusion criteria:
- Stage IV patients
- Patients receiving neo-adjuvant therapy

Timeliness to care was affected by genetic counseling during pandemic (added 7 days) as compared to pre-pandemic (added 4 days).

Implication
Overall, quality of care was not impacted despite the timeliness to care impact, however, adjustments in patient messaging could be implemented to modify patient expectations should future healthcare crises arise.